Introduction {#Sec1}
============

Alopecia universalis (AU) is a variant of alopecia areata (AA) that can affect both children and adults and is associated with the complete loss of all body hair \[[@CR1]\]. It is well known that the etiology of AU is related to a complex interaction between genetic and immune abnormalities that target the hair follicle. T cells have been shown to be important effector cells in the appearance of AU, as they express cytokines---particularly interferon gamma---that target the hair follicle \[[@CR2]\]. While several therapies for AU have been tested, they have all shown only partial or no clinical efficacy \[[@CR3]\]---there are currently no effective therapies for AU. In the past 3 years, a few reports have been published suggesting that some AU patients appear to respond to Janus kinase inhibitors (JAKi), implying that JAKi should be evaluated as a promising novel therapy \[[@CR4], [@CR5]\]. JAKi downregulate interferon expression. Given that the expression of interferon is known to be increased in AU, this could explain the reported response of AU to JAKi \[[@CR6]\]. In this paper, we report the short-term follow-up of four cases of AU in Brazil that remitted after the administration of tofacitinib. The individual aspects of each case are discussed and compared to the limited literature available on this topic at the present time.

Case Series {#Sec2}
===========

*Patient 1*: Male, 38 years of age, who had developed AU 10 years earlier. The patient was initially treated with oral, topical, and intralesional corticosteroids followed by minoxidil, methotrexate, and cyclosporine, all with no response. He also presented with dystrophic fingernails. On examination, he showed a total absence of eyebrows, eyelashes, beard, hair on the trunk, scalp, genitals, arms, and legs. He was started on 5 mg of tofacitinib twice a day---an off-label indication with prior patient consent. After 2 months he developed initial hair growth on the scalp, and there was progressive hair growth after 9 months of therapy (Fig. [1](#Fig1){ref-type="fig"}). Currently, the hair is still growing despite a reduction in the dose to 5 mg a day \[[@CR5]\].Fig. 1Patient 1: before and 9 months after the introduction of tofacitinib 10 mg daily

*Patient 2*: Female, 20 years of age, who had developed AU at age ten and had tried several treatments, including oral and intralesional steroids, methotrexate, and cyclosporine, all with no detectable response. After 6 weeks of therapy with tofacitinib 5 mg twice a day, it was possible to observe partial growth of scalp, eyebrow, and axillary hair (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Patient 2: before and 10 months after the introduction of tofacitinib 10 mg daily

*Patient 3*: Male, 45 years of age, who had developed rheumatoid arthritis 7 years earlier. The patient was treated initially with leflunomide, then prednisone 5 mg for 2 years, which was followed by etanercept, leading to clinical remission of the disease. Two years ago the patient presented with diffuse pruritus, erythematous skin, and initial hair loss on the eyebrows. Leflunomide was initially discontinued and a conventional antiallergic medication was administered but the skin disease persisted. Etanercept was discontinued and abatacept was introduced, but the joint disease remained active and the clinical picture for the skin evolved to alopecia universalis. Tofacitinib was started at 5 mg twice a day, and hair growth appeared on the scalp, eyebrows, and skin after 7 months (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Patient 3: hair growth after 7 months of tofacitinib 10 mg daily

*Patient 4*: Female, 60 years of age, who had developed seropositive rheumatoid arthritis 2 years earlier. The patient was in remission due to treatment with etanercept and methotrexate when progressive hair loss developed. All medications were withdrawn; subsequent treatment with oral prednisone and intralesional triamcinolone injections had no effect. She progressed to universal alopecia and her arthritis became active again. Tofacitinib was introduced, and 6 months after that the patient's arthritis had improved and the alopecia had fully resolved (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Patient 4: hair growth 1 and 4 months after the introduction of tofacitinib 10 mg daily

This case series complied with the ethical standards of the AACD Hospital. All procedures followed the ethical standards for human experimentation, and informed consent was obtained from all patients.

Discussion {#Sec3}
==========

Tofacitinib citrate is a small molecule that selectively inhibits Janus kinase 1 and 3 and was approved for the treatment of moderate to severe rheumatoid arthritis \[[@CR7]\]. Since it affects various T cell effector functions, it is also being evaluated for the treatment of other autoimmune inflammatory conditions of the skin, such as psoriasis and atopic dermatitis. Alopecia areata and universalis are considered to be autoimmune in their pathogenesis due to the attack of T cells on hair follicles, which leads to transient or permanent nonscarring hair loss \[[@CR8]\]. Recently, new molecular pathways that are involved in AA were discovered, including autophagy/apoptosis, transforming growth factor/Tregs, and Janus kinase signaling \[[@CR6]\]. In this paper, we have presented four Brazilian patients who developed progressive hair growth upon treatment with tofacitinib at the recommended dose approved for the treatment of rheumatoid arthritis. All four cases had a clinical diagnosis and no biopsy was performed in any of the patients. There are very few reports on this topic in the literature. The first was from the Yale Dermatology Group, who reported that tofacitinib appeared to "kill two birds with one stone:" alopecia was reversed in a patient with psoriasis \[[@CR9]\]. That was followed by the largest report yet from the same group---Liu and coworkers reported on 90 patients who had alopecia areata or variants of it. These results are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Clinical response of patients with alopecia to tofacitinibMagnitude of clinical response\
SALT scorePercentage of patients (%)Number of patientsComplete response (\>90%)2013Intermediate response (51--90%)38.425Moderate response (6--50%)18.512No response (\<5%)23.115TherapyPercentage of patients (%)Number of patientsStandard monotherapy. Tofacitinib 5 mg BID43.125Adjuvant therapy56.937Tofacitinib \>5 mg BID29.219Tofacitinib 5 mg BID + prednisone13.89

In the report by the Yale group, almost 60% of the patients showed a \>50% change in the alopecia score (SALT severity of alopecia score tool), which was sustained for variable periods of time.

The duration of the response varied from 4 to 18 months. The lack of a control group makes the conclusions of the study somewhat limited, but the results do appear to confirm those given in other isolated reports from a few groups that are available in the literature \[[@CR10]\]. In one of the reported cases, initial signs of hair regrowth were observed in the same timeframe as reported by Azengruber and coauthors, but the efficacy of the drug quickly waned again, leading to a relapse of the disease \[[@CR11]\]. In a recently released report, the authors conducted a review and suggested that hair growth following tofacitinib treatment may be partial and transient for some patients \[[@CR12]\]. In our cases, the efficacy of tofacitinib persisted; indeed, reducing the dose by half in one of those cases did not affect the positive response (see Fig. [1](#Fig1){ref-type="fig"}). Thus, even though tofacitinib is a promising new treatment option, we need to learn more about its potential, including the appropriate duration of treatment, the maintenance dose, the possibility of relapse if the drug is discontinued, and the loss of response during treatment, as described in one of the reports in the literature. None of our patients developed adverse events, but it is important to monitor for such effects (including infections and hyperlipidemia) during long-term therapy.

Patient 3 in this report developed alopecia areata during anti-TNF treatment. A few such cases have been reported previously \[[@CR13], [@CR14]\]. It is worth noting that the induction of other autoimmune diseases by prolonged anti-TNF treatment has been extensively reported in the medical literature \[[@CR13], [@CR14]\].

The possible application of JAKi to other autoimmune disorders such as psoriasis and inflammatory bowel disease is currently being researched \[[@CR15]\]. Nail dystrophy is a heterogeneous skin condition, but in some subtypes its development has autoimmune origins. We recently reported that tofacitinib appears to be beneficial in patients with this nail disorder, which can also be associated with other rheumatic disorders such as psoriatic arthritis and is observed in approximately 50% of AU patients \[[@CR16]\].

The long-term safety of tofacitinib in patients with rheumatic disease will be closely monitored in years to come, as will its long-term safety in patients with AU. Tofacitinib is similar to biologics in that long-term use can lead to opportunistic infections, in particular those associated with persistent viral infections. In such cases vaccination can help patients who require the long-term use of tofacitinib \[[@CR17]\].

Conclusions {#Sec4}
===========

In conclusion, targeting the intracellular JAK signaling pathway appears to be a promising therapeutic strategy for AA patients, and the future should bring new information along with the advent of second-generation selective JAK inhibitors which are currently being investigated. It is expected that prospective randomized controlled trials will be performed to determine the real efficacy of tofacitinib in patients with AA only or AA in association with other rheumatic diseases.
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